SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
139,800
+700 (0.50%)
At close: Nov 28, 2025
39.94%
Market Cap10.95T
Revenue (ttm)675.41B
Net Income (ttm)320.47B
Shares Out78.31M
EPS (ttm)4,092.19
PE Ratio34.16
Forward PE44.12
Dividendn/a
Ex-Dividend Daten/a
Volume490,024
Average Volume430,613
Open143,700
Previous Close139,100
Day's Range137,700 - 144,100
52-Week Range86,900 - 144,100
Beta0.83
RSI76.03
Earnings DateNov 5, 2025

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilep... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 246
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.